GEN Exclusives

More »

GEN News Highlights

More »
Jul 31, 2013

CST Licenses NSCLC Dx Technology to Cepheid

  • Danvers, MA-based Cell Signaling Technology (CST) has granted molecular diagnostics firm Cepheid a nonexclusive license to its patent for a method to detect gene rearrangements of anaplastic lymphoma kinase (ALK), used in PCR-based tests. Financial terms were not disclosed.

    Using CST technology, Cepheid will be developed a test to detect ALK gene rearrangements in patients with non-small-cell lung cancer (NSCLC), the IP-granting firm said. According to CST, preliminary research has shown that approximately 3% to 5% of NSCLC tumors show ALK rearrangements. Along with one of its partners, CST said it holds the majority of IP rights for methods to detect EML4-ALK translocation in cancer cells.

    "We are very pleased with the fact that the cooperation of the Cepheid, in which we will develop molecular research and diagnostic solutions for the detection of fusion gene EML4-ALK,” Michael J. Comb, Ph.D., CST president and CEO, said in a statement. “We believe that it is the logical step associated with the development of our portfolio of patents and research in the field of improving the detection of EML4-ALK expression that enable more effective diagnosis and treatment of cancer patients.”

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »